Test Price
2,800 AED✅ Home Collection Available
HOGA1 Gene Primary Hyperoxaluria Type 3 NGS Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO‑accredited next‑generation sequencing with rigorous quality controls for the entire HOGA1 coding region.
- VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection – Available daily from 8 AM to 11 PM across all UAE emirates.
- Post‑Test Clinical Guidance – Telephonic interpretation support from a DHA‑licensed Consultant Medical Geneticist.
- Insurance Assistance – Direct billing verification through WhatsApp +971 54 548 8731.
- DHA Facility License No. 1143 – Fully licensed by the Dubai Health Authority for advanced genetic diagnostic services.
Test Overview & Methodology
This next‑generation sequencing (NGS) test analyses the entire coding region and splice‑site junctions of the HOGA1 gene to confirm or rule out primary hyperoxaluria type 3 – an inherited autosomal recessive metabolic disorder that causes recurrent calcium‑oxalate kidney stones, nephrocalcinosis, and progressive renal impairment. Our DHA‑licensed laboratory delivers a comprehensive genetic result within 14–21 business days, empowering nephrologists and urologists to initiate precise, personalised management and avoid unnecessary surgical interventions.
| Feature | Our Test – HOGA1 NGS | Closest Alternative – Sanger Sequencing |
|---|---|---|
| Diagnostic Precision | >99.9% sensitivity; detects single‑nucleotide variants, small indels, and copy‑number changes across all coding exons | ~95% sensitivity; may miss large deletions, duplications, or deep intronic variants |
| Methodology | Next‑Generation Sequencing (Illumina® platform, ISO‑validated) with bioinformatics pipeline for variant annotation | Capillary electrophoresis (Sanger); single‑amplicon per reaction |
| Turnaround Time | 14–21 business days (3–4 weeks) | 4–6 weeks typical for full gene coverage |
| Sample Requirement | 2–3 mL whole blood in EDTA tube; cold‑chain courier included | Identical sample type but requires clinic visit for draw |
| UAE Home Collection | Included (8 AM–11 PM VIP phlebotomy with real‑time tracking) | Often not available; patient must visit a collection centre |
Physician Insight & Safety Protocols
“A precise molecular diagnosis of primary hyperoxaluria type 3 through complete HOGA1 sequencing allows clinicians to distinguish this milder but still progressive form from the more aggressive types 1 and 2. This distinction directly guides vitamin B6 responsiveness trials, dietary oxalate restriction, and long‑term nephroprotective strategies. As a Consultant Medical Geneticist, I emphasise that the genetic result must always be integrated with the patient‘s full clinical picture, family pedigree, and renal function trends. Our team provides dedicated post‑test counselling to ensure that every individual fully understands their result and its implications for kidney health.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Safety Advisory
Do not discontinue or alter any prescribed medication (e.g., potassium citrate, thiazide diuretics, vitamin B6) without consulting your treating nephrologist or urologist. Changing your treatment plan solely based on a genetic test result can provoke acute stone episodes, metabolic imbalances, or worsening renal function. Always share your genetic report with your specialist before making any therapeutic decisions.
Patient Safety – Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Testing May Be Deferred)
- Inability to provide informed consent or absence of legal guardian consent for minors
- Active life‑threatening condition requiring immediate hospitalisation (e.g., urosepsis, acute renal failure)
- Recent whole‑blood transfusion (within 14 days) that could interfere with germline DNA extraction from leukocytes
- Known active haematological malignancy with circulating tumour DNA
Emergency Red Flags – Seek Immediate Medical Attention
- Sudden, severe flank pain with nausea, vomiting, and inability to pass urine (suggestive of obstructive ureteral stone)
- Fever >38.5 °C with rigours, flank tenderness, and urinary urgency (risk of urosepsis or pyelonephritis)
- Marked reduction in urine output (<400 mL/day), confusion, or peripheral oedema (acute kidney injury)
If you experience any of these symptoms, visit the nearest emergency department immediately. A genetic test result does not override acute clinical judgment.
Patient FAQ & Clinical Guidance
1. What is primary hyperoxaluria type 3 and why does HOGA1 sequencing matter?
Primary hyperoxaluria type 3 (PH3) is an inherited metabolic disorder caused by biallelic pathogenic variants in the HOGA1 gene, leading to overproduction of oxalate and recurrent calcium‑oxalate kidney stones. Unlike the more severe PH1, PH3 often presents with a milder phenotype but still carries a risk of nephrocalcinosis and progressive kidney damage if untreated. Definitive molecular confirmation through complete HOGA1 NGS sequencing eliminates diagnostic uncertainty, enables earlier initiation of stone‑prevention strategies (hydration, dietary modification, and vitamin B6 trial), and avoids unnecessary metabolic stone‑risk profiling or renal biopsies.
2. How is the blood sample collected and do I need to visit a hospital?
No hospital visit is required. A certified phlebotomist arrives at your home or office between 8 AM and 11 PM, seven days a week, to draw a small 2–3 mL whole‑blood sample into an EDTA tube. The specimen is immediately placed in a temperature‑controlled cold‑chain transport kit and couriered directly to our ISO‑accredited laboratory in Dubai Healthcare City. You remain in the comfort of your residence throughout the process.
3. When will I receive my HOGA1 genetic report and how is it delivered?
Your comprehensive report is ready within 14–21 business days (3–4 weeks) from sample receipt. It is delivered through a secure, DHA‑compliant online portal with multi‑factor authentication. The report details all detected variants, their zygosity, classification according to ACMG/AMP guidelines, and a clinical interpretation with actionable recommendations for your nephrologist or genetic counsellor. A follow‑up tele‑consultation with our Consultant Medical Geneticist is included to discuss the results and answer your questions.
4. Does my insurance cover the HOGA1 NGS genetic test, and how do I verify coverage?
We offer direct insurance billing assistance for most UAE‑based health insurance plans. Simply send a message via WhatsApp to +971 54 548 8731 with your policy details and member ID. Our insurance team will verify your outpatient genetic testing coverage, including any pre‑authorisation requirements, and inform you of your estimated out‑of‑pocket cost before the test is initiated.
5. What dietary or medication restrictions should I follow before the blood draw?
No special dietary restrictions are needed. You may eat, drink, and take your regular medications as prescribed. However, please inform our team if you have received a blood transfusion within the past 14 days or if you are currently taking anticoagulant (blood‑thinning) therapy, as this may affect sample suitability. A mandatory pre‑test genetic counselling session will review your full medical history and family pedigree to ensure the test is appropriate for your clinical situation.
UAE Regulatory & Data Privacy Adherence
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – All genomic and personal data are encrypted, stored on UAE‑sovereign servers, and never shared with third parties without your explicit written consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Electronic health information systems comply with national cybersecurity standards to protect patient data integrity and confidentiality.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – All clinical procedures, including phlebotomy and genetic counselling, are performed under informed consent and in accordance with established medical liability standards.
- ISO 9001:2015 Certification – Our laboratory operates under Certificate No. INT/EGQ/2509DA/3139, ensuring consistent quality management across all diagnostic workflows.
- DHA Facility License No. 1143 – Licensed by the Dubai Health Authority for advanced genetic testing services at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | HOGA1 Gene Primary Hyperoxaluria Type 3 NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 14–21 business days (3–4 weeks) |
| Sample Type / Matrix | Peripheral whole blood (2–3 mL in EDTA tube); VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® platform, ISO‑validated, with full HOGA1 coding region and flanking intronic coverage |
| ICD-10-CM Code | E72.53 |
| LOINC Code | 94735-4 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians